Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Ruthigen, Pulmatrix ink merger agreement

Monday, March 16, 2015 01:41 PM

Ruthigen, a biopharmaceutical company based in Santa Rosa, Calif., and Pulmatrix, a Lexington, Mass.-based clinical stage biotech, have entered into a definitive merger agreement. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen.

More... »

Quest Diagnostics

XBiotech launches cancer patient directed web site and call center

Monday, March 16, 2015 09:00 AM

XBiotech, an Austin, Texas-based developer of next generation therapeutic antibodies, has launched a web site and call center to help patients with metastatic colorectal cancer learn about its U.S. pivotal phase III clinical trial. The phase III study, Xilonix Colorectal cancer Immunotherapy Treatment Evaluation (XCITE), assesses XBiotech's True Human monoclonal antibody (Xilonix) for the treatment of metastatic colon cancer.

More... »


The Value of Perseverance in the Job Hunt

Monday, March 16, 2015 08:00 AM

The desire to progress along a career path from investigative site to industry is especially strong for ambitious study coordinators who have a CRA or clinical management position as a career goal.

More... »

Western Institutional Review Board receives ISO 9001:2008 certification

Monday, March 16, 2015 08:00 AM

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software, has announced Western Institutional Review Board (WIRB) has been certified to ISO 9001:2008 by BSI, confirming it operates an excellent quality management system.

More... »

Par Pharmaceutical files for IPO

Friday, March 13, 2015 12:55 PM

Par Pharmaceutical Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered by Par Pharmaceutical and its shareholders, and the price range for the offering, have not yet been determined.

More... »

Ember, Mariel Therapeutics ink merger agreement

Friday, March 13, 2015 12:33 PM

Ember Therapeutics, a Boston-based biotech discovering and developing novel obesity and diabetic related therapies, will merge with Mariel Therapeutics, a privately held, New York-based biotech developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7.

More... »

Society for Clinical Research Sites expands relationship with Acurian

Friday, March 13, 2015 12:30 PM

The Society for Clinical Research Sites (SCRS), a Ellicott City, Md.-based global trade organization representing clinical research sites, has announced an expanded relationship with Acurian, a full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD.

More... »

U.K. industry paid $456.7M in 2014 to underwrite medicines bill

Friday, March 13, 2015 12:28 PM

The Association of the British Pharmaceutical Industry (ABPI) and the U.K. Department of Health have announced a fourth quarter payment from industry of $119.3 million to underwrite the growth of the medicines bill under the 2014 Pharmaceutical Price Regulation Scheme (PPRS). This takes the total payment made by industry during 2014 to $456.7 million.

More... »

Icon rides latest outsourcing wave with launch of medical device and diagnostics research group

Friday, March 13, 2015 12:26 PM

Global CRO Icon has packaged a combination of its services to create a medical device and diagnostics research group designed to provide global clinical trials, health economics and pricing and market access tools.

More... »

23andMe to create therapeutics group, names Richard Scheller CSO

Thursday, March 12, 2015 01:03 PM

23andMe, a personal genetics company based in Mountain View, Calif., has created a new therapeutics group and has named Richard Scheller, Ph.D., to lead it as chief science officer and head of therapeutics. Scheller retired in December 2014 from a 14-year career at Genentech, where he was executive vice president of research and early development.

More... »

CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs